-
Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second line treatment. Clin Lymp Myel & Leuk 18, 353-360, 2018
Okada M, Fukushima T et al,
-
Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103, 686-692, 2016
Masaki Y, Fukushima T et al,
-
Isolation of vascular smooth muscle antigen-reactive CD4(+)αβTh1 clones that induce pulmonary vasculitis in MRL/Mp-Fas(+/+) mice. Cell Immunol 303, 50-54, 2016
Fujita Y, Fukushima T et al,
-
Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. Med Oncol 32, 232, 2015
Sakai T, Fukushima T et al,
-
Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. J Infect Chemother 21, 16-22, 2015
Nakane T, Fukushima T et al,
-
t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015 Feb 27;5:e285. doi: 10.1038/bcj.2015.6.
Narita T, Fukushima T et al,
-
CD14(+) follicular dendritic cells in lymphoid follicles may play a role in the pathogenesis of IgG4-related disease. Biomedical Research 36, 143-153, 2015
Satoh-Nakamura T, Fukushima T et al,
-
Decreased Expression of Innate Immunity-Related Genes in Peripheral Blood Mononuclear Cells from Patients with IgG4-Related Disease. PLoS One. 2015 May 14;10(5):e0126582. doi: 10.1371/journal.pone.0126582. eCollection 2015
Nakajima A, Fukushima T et al,
-
Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice. J Immunol 192, 979-984, 2014
Fujita Y, Fukushima T et al,
-
Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53, 79-85, 2013
Masaki Y, Fukushima T,et al,
-
Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.Exp Hematol 41, 894-902, 2013
Takamatsu H, Fukushima T et al,
-
Daily 500 mg valacyclovir is effective for prevention of varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res 32: 5437-5440, 2012
Fukushima T et al,
-
Low dose cytarabine plus aclarubicin for patients with previous untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline. Anticancer Res 32: 1347-1354, 2012
Fukushima T et al,
-
A rondomized comparison of modified intermediate-dose Ara-C versus high dose Ara-C in post-remission therapy for acute myeloid leukemia. Anticancer Res 32: 643-648, 2012
Fukushima T et al,
-
Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia. Int J Hematol 96: 357-363, 2012
Takami A, Fukushima T et al,
-
Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 31: 1741-1744, 2011
Fukushima T, et al,
-
Rapid response of plasmacytoma to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma. Am J Hematol 86: 893, 2011
Fukushima T, et al,
-
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: Once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res 31: 2297-2302, 2011
Fukushima T et al,
-
DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1 - analysis of their binding with TGF- superfamily proteins. FEBS J 277: 4278-89, 2010
Tanaka M, Fukushima T et al,
-
Cisplatin Augments FAS-Mediated Apoptosis through Lipid Rafts. Anticancer Res 30: 2065-72, 2010 21. Cao Y, Fukushima T et al, Synergistic Effects of Topoisomerase I Inhibitor, SN38 on Fas-mediated Apoptosis. Anticancer Res 30: 3911-3917, 2010
Huang CR, Fukushima T et al,
-
Synergistic Effects of Topoisomerase I Inhibitor, SN38 on Fas-mediated Apoptosis. Anticancer Res 30: 3911-3917, 2010
Cao Y, Fukushima T et al,
-
Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas. Anticancer Res 30: 3791-4, 2010
Fukushima T et al,
-
MRSA-pyomyositis in a patient with acute myelogenous leukemia after intensive chemotherapy. Anticancer Res 29: 3361-4, 2009
Fukushima T et al,
-
Proposal for a new clinical entity, IgG4-positive multi-organ lymphoproliferative syndrome: Analysis of 64 cases of IgG4-related disorders.Ann Rheum Dis 68: 1310-5, 2009
Masaki Y, Fukushima T et al,
-
Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. Int J Hematol 89:600-10, 2009
Masaki Y, Fukushima T et al,
-
Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes. Leuk Lymph 49; 809-14, 2008
Yamashita T, Fukushima T, Ueda T.
-
Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cells. Int Immunol 20: 1427-37, 2008
Jin ZX, Fukushima T et al,
-
Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patients with systemic lupus erythematosus. Lupus 17: 210-4, 2008
Fukushima T et al,
